Biotech company Biogen (NASDAQ:BIIB) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 7.3% year on year to ...

Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look ...

NasdaqGS:BIIB 1 Year Share Price vs Fair Value Explore Biogen's Fair Values from the Community and select yours ...

What Happened? A number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation ...

Biogen (NASDAQ:BIIB) stock rises as Q2 2025 results surpass expectations, driven by Alzheimer's drug Leqembi developed with Eisai (ESALF). Read more here.

Biogen Inc. (NASDAQ:BIIB) is one of the top cheap pharmaceutical stocks to buy now. BofA lowered the firm’s price target on Biogen Inc. (NASDAQ:BIIB) to $142 from $143 on August 1, keeping a Neutral ...

Biotech company Biogen (NASDAQ:BIIB) in Q2 CY2025, with sales up 7.3% year on year to $2.65 billion. Its non-GAAP profit of $5.47 per share was 41.3% above analysts’ consensus estimates. Is now the ...

Wall Street analysts forecast that Biogen Inc. (BIIB) will report quarterly earnings of $3.94 per share in its upcoming release, pointing to a year-over-year decline of 25.4%. It is anticipated ...

Investors in Biogen Inc (Symbol: BIIB) saw new options become available today, for the August 29th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BIIB ...

Biogen (BIIB) delivered earnings and revenue surprises of +39.19% and +13.89%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Investors in Biogen Inc (Symbol: BIIB) saw new options begin trading today, for the September 5th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BIIB ...